NEXTBio Capital Management LP
Regulatory profile
From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.
Portfolio style
Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.
Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.7%; sector active share 90.9% against the combined 13F book's sector weights.
Over time 3 measured quarters
How the bands are measured
Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.
Clone Performance
Build a hypothetical price-return history from this filer's public 13F holdings.
View clone backtestPortfolio Concentration
22 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026Portfolio Trend
Sector Breakdown
As of Jun 30, 2026| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $217,397,093 |
Last Quarter's Activity
Export CSVAdded To
Positions the filer increased| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| STTK | Shattuck Labs, Inc. | +577,441 | 3,727,348 | $25,867,795 | |
| IVA | Inventiva S.A. | +454,500 | 1,787,984 | $6,758,579 | |
| ORIC | Oric Pharmaceuticals, Inc. | +182,505 | 706,124 | $7,647,322 | |
| GPCR | Structure Therapeutics Inc. | +179,257 | 312,496 | $16,771,660 | |
| PCVX | Vaxcyte, Inc. | +12,000 | 107,223 | $6,232,872 | |
| PVLA | Palvella Therapeutics, Inc. | +7,223 | 89,909 | $13,739,893 | |
| RYTM | Rhythm Pharmaceuticals, Inc. | +5,680 | 131,758 | $14,629,090 | |
| No positions match the current search. | |||||
Trimmed
Positions the filer reduced| Ticker | Company | Δ Shares | Shares | Value | Open |
|---|---|---|---|---|---|
| CMPS | COMPASS Pathways plc | −245,648 | 1,775,759 | $25,126,989 | |
| VOR | Vor Biopharma Inc. | −110,803 | 889,164 | $16,369,509 | |
| EVMN | Evommune, Inc. | −65,000 | 119,063 | $1,582,347 | |
| PTGX | Protagonist Therapeutics, Inc | −10,286 | 219,333 | $26,885,839 | |
| COGT | Cogent Biosciences, Inc. | −113 | 131,075 | $5,072,602 | |
| No positions match the current search. | |||||
Sold Out
Positions the filer fully exited| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
Reduced | 219,333 | $26,885,839 | 12.37% | |
| STTK |
Shattuck Labs, Inc.
Healthcare
|
Added | 3,727,348 | $25,867,795 | 11.90% | |
| CMPS |
COMPASS Pathways plc
Healthcare
|
Reduced | 1,775,759 | $25,126,989 | 11.56% | |
| GPCR |
Structure Therapeutics Inc.
Healthcare
|
Added | 312,496 | $16,771,660 | 7.71% | |
| VOR |
Vor Biopharma Inc.
Healthcare
|
Reduced | 889,164 | $16,369,509 | 7.53% | |
| RYTM |
Rhythm Pharmaceuticals, Inc.
Healthcare
|
Added | 131,758 | $14,629,090 | 6.73% | |
| PVLA |
Palvella Therapeutics, Inc.
Healthcare
|
Added | 89,909 | $13,739,893 | 6.32% | |
| XENE |
Xenon Pharmaceuticals Inc.
Healthcare
|
Held | 183,225 | $11,059,461 | 5.09% | |
| ZBIO |
Zenas BioPharma, Inc.
Healthcare
|
Held | 426,736 | $10,830,559 | 4.98% | |
| ORIC |
Oric Pharmaceuticals, Inc.
Healthcare
|
Added | 706,124 | $7,647,322 | 3.52% | |
| IVA |
Inventiva S.A.
Healthcare
|
Added | 1,787,984 | $6,758,579 | 3.11% | |
| CBIO |
Crescent Biopharma, Inc.
Healthcare
|
Held | 372,856 | $6,711,408 | 3.09% | |
| PCVX |
Vaxcyte, Inc.
Healthcare
|
Added | 107,223 | $6,232,872 | 2.87% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Reduced | 131,075 | $5,072,602 | 2.33% | |
| VSTM |
Verastem, Inc.
Healthcare
|
Held | 1,306,800 | $4,991,976 | 2.30% | |
| IRON |
Disc Medicine, Inc.
Healthcare
|
Held | 52,655 | $3,851,186 | 1.77% | |
| PHVS |
Pharvaris N.V.
Healthcare
|
NEW | 108,055 | $3,736,541 | 1.72% | |
| ZLAB |
Zai Lab Ltd
Healthcare
|
Held | 183,362 | $3,483,878 | 1.60% | |
| BIOA |
BioAge Labs, Inc.
Healthcare
|
NEW | 100,732 | $2,468,941 | 1.14% | |
| LBRX |
Lb Pharmaceuticals Inc
Healthcare
|
NEW | 68,249 | $2,215,021 | 1.02% | |
| EVMN |
Evommune, Inc.
Healthcare
|
Reduced | 119,063 | $1,582,347 | 0.73% | |
| ACET |
Adicet Bio, Inc.
Healthcare
|
Held | 157,827 | $1,363,625 | 0.63% |
Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.